Apogenix confirms effect of cancer drug

Thursday 26 July 2012

Apogenix GmbH said that a final analysis of data from its Phase 2 proof-of-concept trial of a new drug for glioblastoma, APG101, confirmed the agent’s therapeutic effect as well as its safety and tolerability. The trial recruited 84 patients in 25 centres in Europe.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Germany